For decades, women were told the same thing: hormone replacement therapy was a short-term fix. Five years maximum. Get through the worst of it and then get off. The goal was the lowest dose for the shortest possible time.
That guidance shaped an entire generation of medical practice — and left millions of women either never starting HRT at all, stopping it prematurely when they still needed it, or suffering through years of unnecessary symptoms because their doctor told them their time was up.
Here's what the science actually says now: there is no arbitrary time limit on hormone therapy. And for many women, staying on it long-term is not just acceptable — it is the right decision for their long-term health.
Where the "Five Year Rule" Came From
The short-term-only guidance originated largely from the Women's Health Initiative study, published in 2002, which raised concerns about breast cancer, cardiovascular disease, and other risks associated with hormone therapy. Physicians responded — understandably — by pulling back dramatically on prescribing, and the "lowest dose, shortest duration" mantra became standard practice.
What has become clear in the two decades since is that the WHI study had significant limitations. It used older women, started therapy many years after menopause, and used synthetic progestins and oral conjugated equine estrogen — not the transdermal bioidentical estradiol and micronized progesterone that represent modern hormone therapy practice. The results were overcorrected for, and women paid the price.
What the Guidelines Say Now
Both the American College of Obstetricians and Gynecologists and The Menopause Society now agree that there is no maximum duration for hormone therapy use. Decisions about how long to continue are now driven by individual health factors, symptoms, and personal goals.
The Menopause Society's position is that for most healthy symptomatic women who are younger than 60 and within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks — and that personalization with shared decision-making and periodic reevaluation is the appropriate framework, rather than a predetermined time limit.
The Menopause Society advises that women aged older than 65 can continue using hormone therapy with appropriate counseling and risk assessment — and a retrospective analysis presented at their 2024 annual meeting demonstrated that it is not unusual for women as old as 80 to still benefit from it.
In other words: the question is not "how long is too long?" The question is "does this woman still benefit, and does she have a contraindication?" If the answer is yes to the first and no to the second, continuing therapy is appropriate.
The FDA Black Box — Gone
This is significant and recent, and most women don't know about it yet.
In November 2025, the FDA initiated removal of the black box warning on hormone therapy labeling — stating the goal was to provide current, accurate, and balanced information about the benefits and risks so that women, in consultation with their healthcare providers, can make the best decisions for their health.
The FDA stated that there is literature to support risk reduction for all-cause mortality, fractures, heart attack, cognitive decline, and Alzheimer's disease with hormone therapy.
That black box warning — which listed cardiovascular disease, breast cancer, and dementia as risks — shaped how doctors talked about HRT for over twenty years. Its removal is an acknowledgment that the evidence no longer supports those warnings in the way they were presented. This is a meaningful shift, and it matters for every woman considering or currently on hormone therapy.
When HRT Should Be Stopped
The updated guidance is not that everyone should stay on HRT forever. It's that the decision to stop should be based on clinical reality — not an arbitrary calendar date.
There are genuine contraindications to hormone therapy that warrant stopping or not starting. These include:
- Active or history of estrogen-receptor positive breast cancer
- Unexplained vaginal bleeding
- Active liver disease
- History of blood clots or pulmonary embolism — particularly relevant for oral estrogen, much less so for transdermal
- Active cardiovascular disease in certain contexts
- History of stroke
Outside of these contraindications, if a woman is feeling well on HRT, has no new risk factors, and continues to benefit — there is no clinical reason to stop simply because she has reached a certain age or a certain number of years on therapy.
Why We Prefer Transdermal Estradiol — Especially After 50
This is where the route of administration becomes increasingly important as women age, and it is something we are deliberate about at The Lee Clinic.
As women move into their 50s and beyond, certain cardiovascular and clotting risks naturally increase with age. Oral estrogen — because it passes through the liver — stimulates the production of clotting factors and can raise blood pressure and triglycerides in some women. These effects are modest in younger women but become more clinically relevant as background cardiovascular risk rises with age.
Transdermal estradiol bypasses the liver entirely. It delivers estradiol directly into the bloodstream — the same molecule your ovaries produced naturally — without the first-pass hepatic effect. The Menopause Society specifically notes that transdermal routes of administration and lower doses may decrease the risk of venous thromboembolism and stroke.
This is why, for women over 50 — and honestly for most women at any age — transdermal estradiol is our preferred approach. A patch, gel, or cream applied to the skin delivers consistent, physiologic levels of estradiol without the liver seeing a bolus of hormone with each dose. The safety profile is more favorable, the delivery is more consistent, and it more closely mimics what the body was doing naturally.
For women who are already on oral estrogen and feeling well, this is a conversation worth having — not because oral estrogen is dangerous, but because the transdermal route offers meaningful advantages that become more relevant over time.
Long-Term HRT Is About More Than Symptoms
This is perhaps the most important reframe in modern menopause medicine: hormone therapy is not just about hot flashes. It never was.
Long-term estrogen therapy has documented benefits for bone density, cardiovascular health, cognitive function, and metabolic health — benefits that continue as long as therapy continues, and that are lost when therapy stops. For a woman who started HRT at 50 and is now 65 and thriving, stopping her hormones does not take her back to where she was at 50. It removes protection that has been working quietly in the background for fifteen years.
The decision to continue or stop HRT at any age should be made the same way we make every clinical decision at The Lee Clinic: with a thorough understanding of the individual patient, her risk factors, her health history, her current labs, and her goals — not based on a number on a calendar.
If you have been told it's time to stop your hormones simply because of how long you have been on them, that conversation deserves a second look.
The Lee Clinic sees patients in person in Winchester and Reston, VA. Telehealth appointments are available for patients in FL, DC, WV, and MD. Call us at 540-542-1700 to schedule.